GlassScriptPhysician profile
Cynthia M Correll
NPI 1609036482
$2,101.51
in general payments reported to CMS, 2019-2025
29 companies · $1,257 in 2025
The $1,257 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $175 · 2024: $670 · 2025: $1,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,066 · Debt Forgiveness: $35.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,065.90 |
| Debt Forgiveness | $35.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $341.32 | 2023-2025 | Ubrelvy, Qulipta |
| Alexion Pharmaceuticals, INC. | $174.79 | 2024-2025 | Ultomiris |
| Sk Life Science, INC. | $162.68 | 2024-2025 | |
| Ucb, INC. | $149.92 | 2024-2025 | Rystiggo, Briviact, Nayzilam |
| Livanova USA, INC. | $137.16 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Lilly USA, LLC | $109.95 | 2023-2025 | Emgality, Kisunla, Amyvid |
| Jazz Pharmaceuticals INC. | $102.88 | 2023-2025 | |
| Pfizer INC. | $92.26 | 2024-2025 | |
| Catalyst Pharmaceuticals, INC. | $77.21 | 2025 | |
| Merz Pharmaceuticals, LLC | $69.48 | 2024-2025 | Xeomin, Inbrija |
| Lundbeck LLC | $62.67 | 2023-2025 | Vyepti |
| Vanda Pharmaceuticals INC. | $54.35 | 2025 | Ponvory |
| Biogen, INC. | $48.62 | 2024 | Tysabri, Vumerity |
| Teva Pharmaceuticals USA, INC. | $46.63 | 2024-2025 | Austedo Xr, Austedo Xr |
| Eisai INC. | $46.22 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $46.20 | 2025 | Purified Cortrophin Gel |
| Acadia Pharmaceuticals INC | $45.05 | 2025 | Nuplazid |
| Argenx US, INC. | $43.78 | 2024-2025 | Vyvgart Hytrulo |
| Tanabe Pharma America, INC. | $41.43 | 2024-2025 | Radicava |
| Neurelis, INC. | $41.11 | 2024 | Valtoco |
| Baxter Healthcare | $35.61 | 2023-2024 | |
| Amgen INC. | $33.18 | 2023 | Aimovig |
| Alnylam Pharmaceuticals INC. | $24.06 | 2024 | Onpattro |
| Medtronic, INC. | $21.47 | 2023 | Percept PC Brainsense |
| Takeda Pharmaceuticals U.S.A., INC. | $21.38 | 2025 | Hyqvia |
| Tg Therapeutics, INC. | $20.99 | 2024 | |
| Xeris Pharmaceuticals, INC. | $20.17 | 2025 | Keveyis |
| Neurocrine Biosciences, INC. | $15.70 | 2025 | |
| Celgene Corporation | $15.24 | 2025 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Correll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.